LABORATORIOS FARMACEUTICOS ROVI (ROVI.MC) Financials
ROVI.MC Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-09-30 | 830.7 million | 276.1 million |
| 2023-06-30 | 899.8 million | 380.0 million |
| 2023-03-31 | 885.2 million | 316.4 million |
| 2022-12-31 | 878.7 million | 357.3 million |
ROVI.MC Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-09-30 | -8.9 million | ? |
| 2023-06-30 | 14.8 million | ? |
| 2023-03-31 | 19.6 million | ? |
| 2022-12-31 | 34.6 million | ? |
ROVI.MC Net Income
| Date | Net Income |
|---|---|
| 2023-09-30 | 68.3 million |
| 2023-06-30 | 24.7 million |
| 2023-03-31 | 61.2 million |
| 2022-12-31 | 100.0 million |
ROVI.MC Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-09-30 | 56.4 million | - | - |
| 2023-06-30 | 155.4 million | 54.5 million | - |
| 2023-03-31 | 141.5 million | - | - |
| 2022-12-31 | 124.9 million | 59.4 million | 17.9 million |
ROVI.MC Shares Outstanding
ROVI.MC Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-09-30 | 8.6 million | 5.7 million | - | - |
| 2023-06-30 | 13.3 million | 5.6 million | 54.0 million | - |
| 2023-03-31 | 4.9 million | 5.2 million | 29.2 million | - |
| 2022-12-31 | 32.9 million | 7.7 million | 50.8 million | - |
ROVI.MC Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-09-30 | 214.0 million | 77.8 million |
| 2023-06-30 | 179.2 million | 87.8 million |
| 2023-03-31 | 201.6 million | 75.6 million |
| 2022-12-31 | 242.2 million | 65.7 million |
ROVI.MC
Price: €85
Dividend Yield: 0.01%
Forward Dividend Yield: 1.23%
Payout Ratio: 29.03%
Dividend Per Share: 1.05 EUR
Earnings Per Share: 3.20 EUR
P/E Ratio: 17.96
Exchange: MCE
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 4.2 billion
Average Dividend Frequency: 1
Years Paying Dividends: 16
DGR3: 24.13%